SK bioscience Co.,Ltd. (302440.KS)
KRW 38650.0
(-0.26%)
KRW 38650.0
(-0.26%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 80.64 Billion KRW | -56.97% |
| 2022 | 187.4 Billion KRW | 38.77% |
| 2021 | 135.04 Billion KRW | 92.17% |
| 2020 | 70.27 Billion KRW | 93.18% |
| 2019 | 36.37 Billion KRW | 14.12% |
| 2018 | 31.87 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 129.22 Billion KRW | 26.75% |
| 2024 Q1 | 101.95 Billion KRW | 26.41% |
| 2023 Q1 | 196.05 Billion KRW | 4.61% |
| 2023 FY | 80.64 Billion KRW | -56.97% |
| 2023 Q4 | 80.64 Billion KRW | -42.06% |
| 2023 Q3 | 139.19 Billion KRW | -40.35% |
| 2023 Q2 | 233.35 Billion KRW | 19.03% |
| 2022 Q3 | 220.09 Billion KRW | 29.47% |
| 2022 Q2 | 170 Billion KRW | 13.47% |
| 2022 Q1 | 149.82 Billion KRW | 10.94% |
| 2022 FY | 187.4 Billion KRW | 38.77% |
| 2022 Q4 | 187.4 Billion KRW | -14.85% |
| 2021 Q4 | 135.04 Billion KRW | 0.02% |
| 2021 Q2 | 104.32 Billion KRW | 44.44% |
| 2021 Q3 | 135.02 Billion KRW | 29.42% |
| 2021 FY | 135.04 Billion KRW | 92.17% |
| 2021 Q1 | 72.23 Billion KRW | 2.78% |
| 2020 Q2 | 63.3 Billion KRW | 31.74% |
| 2020 FY | 70.27 Billion KRW | 93.18% |
| 2020 Q4 | 70.27 Billion KRW | 14.84% |
| 2020 Q3 | 61.19 Billion KRW | -3.33% |
| 2020 Q1 | 48.05 Billion KRW | 32.1% |
| 2019 Q2 | 47.21 Billion KRW | 28.04% |
| 2019 FY | 36.37 Billion KRW | 14.12% |
| 2019 Q3 | 41.89 Billion KRW | -11.26% |
| 2019 Q4 | 36.37 Billion KRW | -13.17% |
| 2019 Q1 | 36.87 Billion KRW | 15.69% |
| 2018 Q4 | 31.87 Billion KRW | -3.12% |
| 2018 Q3 | 32.9 Billion KRW | 0.0% |
| 2018 FY | 31.87 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ORIENT BIO Inc. | 3.65 Billion KRW | -2106.906% |
| Green Cross Holdings Corporation | 579.72 Billion KRW | 86.088% |
| Green Cross Holdings Corporation | 516.24 Billion KRW | 84.378% |
| Pharmicell Co., Ltd. | 20.87 Billion KRW | -286.393% |
| Green Cross Corporation | 516.24 Billion KRW | 84.378% |
| GeneOne Life Science, Inc. | 14.89 Billion KRW | -441.382% |
| Celltrion, Inc. | 3041.45 Billion KRW | 97.348% |
| Samsung Biologics Co.,Ltd. | 2641.36 Billion KRW | 96.947% |
| SK Biopharmaceuticals Co., Ltd. | 102.52 Billion KRW | 21.337% |
| Prestige BioPharma Limited | 18.1 Billion KRW | -345.503% |